Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative aspects: declining revenue, significant cash burn, and lack of shareholder return plans. Operational and regulatory risks are highlighted, along with competitive pressures. Although there is optimism in clinical programs, management's vague responses in the Q&A section and the absence of new partnerships or positive guidance adjustments contribute to a negative outlook. The stock price is likely to fall between -2% to -8% due to these factors.
Key Financial Performance
Cash, cash equivalents and investments €34.4 million, down from €72 million (year-over-year change: -€37.6 million). The decrease is attributed to cash used in operating activities.
Net cash used in operating activities €16.5 million, down from €33.3 million (year-over-year change: -€16.8 million). The reduction is due to improved operational efficiency.
Total revenue €0.2 million, down from €1.4 million (year-over-year change: -€1.2 million). The decline is due to reduced revenue generation activities.
R&D expense €11.7 million, down from €25.3 million (year-over-year change: -€13.6 million). The decrease is attributed to cost-cutting measures and operational efficiency.
G&A expenses €4 million, down from €6.3 million (year-over-year change: -€2.3 million). The reduction is due to ongoing efforts to streamline operations.
Net loss €15.5 million, or €1.01 per common share, compared with a net loss of €29.4 million, or €1.97 per common share (year-over-year change: -€13.9 million). The improvement is due to reduced expenses in R&D and G&A.
Operating Highlights
AFM24: Achieved clinical proof of concept in non-small cell lung cancer (NSCLC) with early efficacy data showing a 23.5% objective response rate and a 70.6% disease control rate in EGFR mutant cohort.
AFM13 (acimtamig): Reported an 83.3% response rate in heavily pretreated Hodgkin's lymphoma patients, with 50% achieving complete response.
AFM28: Demonstrated a 50% complete response rate in acute myeloid leukemia patients at the highest dose cohort, indicating a potential dose response relationship.
Market Positioning: The new CEO, Shawn Leland, aims to secure funding for clinical programs and broaden partnerships with pharmaceutical companies to enhance market positioning.
Operational Efficiency: The company is focused on achieving operational efficiency and excellence, with a commitment to continuous improvement.
Strategic Shift: The new CEO plans to explore creative partnerships and broaden clinical development strategies to reach more patients.
Risk or Challenges
Financial Risks: Affimed's cash and cash equivalents decreased from €72 million at the end of 2023 to €34.4 million by the end of Q2 2024. The company anticipates that its current financial resources will only last into the second half of 2025, indicating potential liquidity risks.
Market Risks: The capital markets have been challenging for biotechs in 2024, which may impact Affimed's ability to secure funding for its clinical programs.
Regulatory Risks: The company plans to engage with regulatory agencies to discuss the best path for potential market approval, indicating that regulatory hurdles could affect the timeline and success of their product launches.
Operational Risks: Affimed has undergone significant organizational changes over the past year, which may pose challenges in achieving operational efficiency and excellence.
Clinical Development Risks: The company is focused on expanding its clinical development strategy, which may involve risks associated with trial design, patient enrollment, and the efficacy of combination therapies.
Competitive Pressures: Affimed operates in a highly competitive biotech environment, particularly in the oncology space, where there are numerous alternative therapies and treatment options available.
Guidance & Outlook
Clinical Programs: Affimed has achieved clinical proof of concept across three assets targeting advanced refractory or relapsed patients, particularly in non-small cell lung cancer, Hodgkin lymphoma, and acute myeloid leukemia.
Funding Commitment: Shawn Leland, the new CEO, is committed to securing funding to support promising clinical programs and engaging with current and prospective investors.
Business Development Strategy: The CEO aims to examine and broaden relationships with pharmaceutical partners to enhance clinical development and patient access.
Operational Efficiency: Affimed is focused on achieving operational efficiency and excellence to deliver value to stakeholders.
Data Readouts: Numerous data readouts are expected in the next 12 to 24 months from ongoing clinical trials.
Cash Position: Affimed ended Q2 2024 with cash and equivalents of €34.4 million, down from €72 million at the end of 2023.
Cash Runway: The company anticipates its cash will finance operations into the second half of 2025.
Revenue Expectations: Total revenue for Q2 2024 was €0.2 million, a decrease from €1.4 million in Q2 2023.
R&D Expenses: R&D expenses for Q2 2024 were €11.7 million, down from €25.3 million in Q2 2023.
Net Loss: Net loss for Q2 2024 was €15.5 million, or €1.01 per share, compared to a net loss of €29.4 million, or €1.97 per share, in Q2 2023.
Shareholder Return Plan
Shareholder Return Plan: Affimed has not announced any specific share buyback or dividend program during this call. The focus remains on securing funding to support clinical programs and enhancing shareholder value through successful execution of clinical development.
Key Q&A
Earnings Word Cloud
AFMD Transcript
The earnings call summary shows a decrease in revenue and cash position, despite reduced expenses and net loss. The Q&A section highlights uncertainties regarding AFM28's FDA path, collaboration strategies, and data maturity. These factors, combined with unclear management responses, suggest investor concerns. The lack of strong positive catalysts and the ongoing financial challenges lead to a negative sentiment, predicting a stock price decrease of -2% to -8%.
The earnings call reveals several negative aspects: declining revenue, significant cash burn, and lack of shareholder return plans. Operational and regulatory risks are highlighted, along with competitive pressures. Although there is optimism in clinical programs, management's vague responses in the Q&A section and the absence of new partnerships or positive guidance adjustments contribute to a negative outlook. The stock price is likely to fall between -2% to -8% due to these factors.
The earnings call reflects mixed sentiment. Financial performance shows reduced losses and operational expenses, but revenue and cash reserves have significantly declined. Promising clinical results, especially in AFM24 and LuminICE-203, are offset by recruitment delays and competitive market risks. The Q&A highlights strong response rates but also reveals management's avoidance of specific timelines, raising uncertainty. No new partnerships or shareholder return changes were announced. Overall, the sentiment is balanced, suggesting a neutral stock price movement over the next two weeks.
The earnings call revealed a sharp revenue decline, clinical trial recruitment challenges, and significant cash burn, with no clear guidance or new partnerships. Q&A highlighted uncertainties, such as management's avoidance of specifics and slower than expected trial enrollment. These factors, combined with competitive pressures and regulatory risks, suggest a strong negative sentiment, likely leading to a stock price decline.
AFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
